title: Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
abstract: Metastasis of lung cancer to soft tissue is rare and patient outcomes are generally poor. There are no reports describing soft tissue metastasis in lung squamous cell carcinoma (SCC), in which gefitinib treatment was effective not only for the primary tumor but also the metastatic lesion. A 61-year-old Asian woman presented to our facility with pain and a mass in the brachium. An additional tumor was identified in the lung. As we suspected soft tissue metastasis of lung cancer, an incisional biopsy was performed, yielding a diagnosis of SCC. The brachial tumor continued to grow and became exposed at the biopsy site when the incisional wound dehisced. Because the biopsied specimen was positive for an epidermal growth factor receptor (EGFR) gene mutation, we commenced gefitinib administration. This treatment resulted in the rapid shrinkage of both the brachial metastasis and the primary tumor, followed by healing of the wound. Therefore, tyrosine kinase inhibitors should be used for cases that present EGFR activating mutations independently from the presence of skin and soft tissue metastases.
authors.affiliation: Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Kana
authors.initials: K
authors.lastname: Kataoka
authors.affiliation: Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Eiji
authors.identifier: http://orcid.org/0000-0002-3429-2238
authors.initials: E
authors.lastname: Osaka
authors.affiliation: Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shimizu
authors.affiliation: Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Okamura
authors.affiliation: Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yoshida
authors.affiliation: Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Tokuhashi
mesh_terms: D001132:Arm / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D011799:Quinazolines / Q000008:administration & dosage* / Q000627:therapeutic use; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D016896:Treatment Outcome
chemical_list: D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib
keywords: Epidermal growth factor receptor (EGFR) gene mutation; gefitinib; lung cancer; soft tissue metastasis; squamous cell carcinoma